Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | AADAC | P22760 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flutamide SCHEMBL3934 | 1.00 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL29349783 | 1.00 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL28162762 | 0.99 | AR (0.97) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL21753660 | 0.99 | AR (0.97) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL679388 | 0.96 | AR (0.93) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL7104567 | 0.95 | AR (0.90) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL1028216 | 0.93 | AR (0.86) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11512367 | 0.91 | AR (0.83) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL19117466 | 0.90 | AR (0.81) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11512254 | 0.90 | AR (0.81) | ARCYP3A4CES2ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10928405-B2 | Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells | ANALIZA, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3080341-B1 | METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190178901-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20160166683-A1 | ADJUVANT IMMUNOTHERAPY FOR THE TREATMENT CANCER, OF CLINICAL MANIFESTATIONS ASSOCIATED WITH THE DISEASES LIKE CACHEXIA AND CORRECTION OF ADVERSE EFFECTS OF DRUGS SUCH AS IMMUNOSUPPRESSION, SECUNDARY CACHEXIA, NEUTROPENIA AND LYMPHOPENIA, COMPRISING THE ASSOCIATION OR COMBINATION OF A BIOLOGICAL RESPONSE MODIFIER SPECIALLY SELECTED AND OTHER SUBSTANCES WITH ANTINEOPLASTIC ACTION AND/OR OTHER TREATMENTS | NUNES LSEU DA SILVA (BR) | 2016-06-16 | — | — | US | disclosed |
| US-20150160246-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2678359-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | Merrimack Pharmaceuticals, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012116317-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| EP-2475366-A1 | SUBSTITUTED (HETEROARYLMETHYL) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| CN-102481294-A | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs | BAYER SCHERING PHARMA AG | 2012-05-30 | — | — | CN | disclosed |
| WO-2011029782-A1 | SUBSTITUTED (HETEROARYLMETHYL) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1140192-B1 | USE OF THE CYCLOOXYGENASE-2 INHIBITOR CELECOXIB AND CAPECITABINE FOR COMBINATION THERAPY IN NEOPLASIA | SEARLE LLC (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-0616812-B1 | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer | BERLEX BIOSCIENCES (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0616812-A1 | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer | BERLEX BIOSCIENCES (US) | 1994-09-28 | — | — | EP | disclosed |